Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Non-Current Liabilities: 2017-2025

Historic Total Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $44.8 million.

  • Aclaris Therapeutics' Total Non-Current Liabilities rose 6.13% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of $56.1 million for FY2024, which is 64.79% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Total Non-Current Liabilities stood at $44.8 million, which was down 4.42% from $46.9 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Total Non-Current Liabilities ranged from a high of $56.1 million in Q4 2024 and a low of $18.0 million during Q2 2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $34.0 million (2023), whereas its average is $35.0 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 36.32% in 2022, then surged by 159.89% in 2025.
  • Aclaris Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $25.5 million in 2021, then fell by 6.26% to $23.9 million in 2022, then surged by 42.52% to $34.0 million in 2023, then surged by 64.79% to $56.1 million in 2024, then increased by 6.13% to $44.8 million in 2025.
  • Its Total Non-Current Liabilities stands at $44.8 million for Q3 2025, versus $46.9 million for Q2 2025 and $45.0 million for Q1 2025.